Evorpacept
- Generic Name
- Evorpacept
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2484949-51-9
- Unique Ingredient Identifier
- X7K762X1IJ
- Background
evorpacept is under investigation in clinical trial NCT04755244 (A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)).
- Associated Conditions
- -
- Associated Therapies
- -
Neoadjuvant Immunoradiotherapy With Evorpacept and Pembrolizumab in HPVOPC (Human Papilloma Virus Oropharynx Cancer)
- First Posted Date
- 2023-03-28
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 29
- Registration Number
- NCT05787639
- Locations
- 🇺🇸
Providence Health & Services, Portland, Oregon, United States
🇺🇸UC San Diego Moores Cancer Center, La Jolla, California, United States
A Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer
Phase 2
Active, not recruiting
- Conditions
- Microsatellite Stable Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2021-12-22
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 80
- Registration Number
- NCT05167409
- Locations
- 🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸Rutgers Cancer insititute, New Brunswick, New Jersey, United States
🇺🇸University of Colorado Cancer Center, Aurora, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath